Intra-Arterial Thrombolysis Within Three Hours of Stroke Onset in Middle Cerebral Artery Strokes
- 86 Downloads
Background and Purpose
The Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial showed improved outcomes in patients with proximal middle cerebral artery (MCA) occlusions treated with intra-arterial (IA) thrombolysis within 6 h of stroke onset. We analyzed outcomes of patients with proximal MCA occlusions treated within 3 h of stroke onset in order to determine the influence of time-to-treatment on clinical and angiographic outcomes in patients receiving IA thrombolysis.
Thirty-five patients from three academic institutions with angiographically demonstrated proximal MCA occlusions were treated with IA thrombolytics within 3 h of stroke onset. Outcome measures included outcomes at 30–90 day follow-up, recanalization rates, incidence of symptomatic intracranial hemorrhage, and mortality in the first 90 days. The endpoints were compared to the IA treated and control groups of the PROACT II trial.
The median admission National Institutes of Health Stroke Scale (NIHSS) score was 16 (range 4–24). The mean time to initiation of treatment was 106 min (range 10–180 min). Sixty-six percent of patients treated, had a modified Rankin Scale (mRS) score of 2 or less at 1–3 month follow-up compared to 40% in the PROACT II trial. The recanalization rate was 77% (versus 66% in PROACT II). The symptomatic intracranial hemorrhage rate was 11% (versus 10% in PROACT II) and the mortality rate was 23% (versus 25% in PROACT II).
Time-to-treatment is just as important in IA thrombolysis as it is in IV thrombolysis, both for improving clinical outcomes and recanalization rates as well.
KeywordsStroke Intra-arterial Thrombolysis Treatment Middle cerebral artery TPA
- 1.Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysis in cerebral arterial occlusion. JAMA. 1958;167:1705–9.Google Scholar
- 3.Furlan A, Higashida RT, Wechsler L, et al. for the PROACT Investigators: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA. 1999;282(21):2003–11. doi:10.1001/jama.282.21.2003.
- 10.Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke. 1988;9(7):802–12.Google Scholar
- 16.Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. JAMA. 1999;82(21):2019–26. doi:10.1001/jama.282.21.2019.Google Scholar
- 18.Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245–51. doi:10.1016/S0140-6736(98)08020-9.PubMedCrossRefGoogle Scholar
- 19.Wardlaw J, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke (Cochrane review). Cochrane Database of Syst Rev. 2003;(3). doi:10.1002/14651858.CD000213.
- 20.Kanter D, Kothari R, Panioloi A, et al. The greater Cincinnati tPA experience after the NINDS trial: does a longer time to treatment within the current 3-hour window reduce efficacy? (Abstract). Presented at 24th Annual American Heart Association International Conference on Stroke and Cerebral Circulation, February 5, 1999; Nashville, TN.Google Scholar